株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

チロシンキナーゼ阻害剤市場:世界の業界分析、規模、シェア、成長、動向、2018~2026年の予測

Tyrosine Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

発行 Transparency Market Research 商品コード 740532
出版日 ページ情報 英文 250 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.60円で換算しております。
Back to Top
チロシンキナーゼ阻害剤市場:世界の業界分析、規模、シェア、成長、動向、2018~2026年の予測 Tyrosine Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日: 2018年10月03日 ページ情報: 英文 250 Pages
概要

当レポートでは、世界のチロシンキナーゼ阻害剤市場について調査し、2026年までの市場成長動向、セグメント別動向、地域別動向、市場に参入する主要企業のプロファイルなどをまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 主な動向
  • 市場分析と予測
    • 市場収益予測

第5章 市場見通し

  • 主なブランド/製品分析
  • 特許・市場独占性分析
  • 認可済み適応の概要
  • 治験分析
  • 近年の業界動向
  • パイプライン分析
  • 主な合併・買収

第6章 製品別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場予測
    • BCR-ABLチロシンキナーゼ阻害剤
    • 上皮成長因子受容体(EGFR)チロシンキナーゼ阻害剤
    • 血管内皮細胞増殖因子(VEGFR)チロシンキナーゼ阻害剤
    • その他
  • 市場の魅力度

第7章 用途別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場予測
    • 慢性骨髄性白血病
    • 肺癌
    • 乳癌
    • 腎細胞癌
    • その他
  • 市場の魅力度

第8章 流通チャンネル別市場分析と予測

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場予測
    • 院内薬局
    • 独立型薬局
    • オンライン薬局
  • 市場の魅力度

第9章 地域別市場分析と予測

  • 主な調査結果
  • 市場予測
  • 市場の魅力度

第10章 北米市場

第11章 欧州市場

第12章 アジア太平洋地域市場

第13章 ラテンアメリカ市場

第14章 中東市場

第15章 アフリカ市場

第16章 競合環境

  • 競合マトリクス
  • 市場概要
  • 企業プロファイル
図表

List of Tables

  • Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
  • Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
  • Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
  • Table 04: Global Other Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
  • Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)
  • Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)
  • Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)
  • Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)
  • Table 09: Overview of Indications Approved, by Molecule (1/8)
  • Table 10: Overview of Indications Approved, by Molecule (2/8)
  • Table 11: Overview of Indications Approved, by Molecule (3/8)
  • Table 12: Overview of Indications Approved, by Molecule (4/8)
  • Table 13: Overview of Indications Approved, by Molecule (5/8)
  • Table 14: Overview of Indications Approved, by Molecule (6/8)
  • Table 15: Overview of Indications Approved, by Molecule (7/8)
  • Table 16: Overview of Indications Approved, by Molecule (8/8)
  • Table 17: BCR-ABL Tyrosine Kinase Inhibitors Pipeline Analysis (1/2)
  • Table 18: BCR-ABL Tyrosine Kinase Inhibitors Pipeline Analysis (2/2)
  • Table 19: EGFR Tyrosine Kinase Inhibitors Pipeline Analysis
  • Table 20: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (1/3)
  • Table 21: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (2/3)
  • Table 22: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (3/3)
  • Table 23: Multi-target Tyrosine Kinase Inhibitors Pipeline Analysis
  • Table 24: Bruton's Tyrosine Kinase Inhibitors Pipeline Analysis (1/2)
  • Table 25: Bruton's Tyrosine Kinase Inhibitors Pipeline Analysis (2/2)
  • Table 26: Aurora Tyrosine Kinase Inhibitors Pipeline Analysis
  • Table 27: Other Tyrosine Kinase Inhibitors Pipeline Analysis (1/3)
  • Table 28: Other Tyrosine Kinase Inhibitors Pipeline Analysis (2/3)
  • Table 29: Other Tyrosine Kinase Inhibitors Pipeline Analysis (3/3)
  • Table 30: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 31: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 32: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 33: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 34: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 35: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 36: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 37: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 38: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 39: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 40: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 41: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 42: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 43: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 44: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 45: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 46: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 47: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 48: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 49: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 50: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 51: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 52: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 53: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 54: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 55: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016-2026
  • Table 56: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026

List of Figures

  • Figure 01: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
  • Figure 02: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 03: Global Tyrosine Kinase Inhibitors Market Value Share, by Product Type (2017)
  • Figure 04: Global Tyrosine Kinase Inhibitors Market Value Share, by Application (2017)
  • Figure 05: Global Tyrosine Kinase Inhibitors Market Value Share, by Distribution Channel (2017)
  • Figure 06: Global Tyrosine Kinase Inhibitors Market Value Share, by Region (2017)
  • Figure 07: Clinical Trial Analysis by Phase
  • Figure 08: Clinical Trial Analysis by Status
  • Figure 09: Clinical Trial Analysis by Completion and Termination Rate
  • Figure 10: Clinical Trial Analysis by Region
  • Figure 11: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 12: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by BCR-ABL TKIs, 2016-2026
  • Figure 13: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by EGFR TKIs, 2016-2026
  • Figure 14: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by VEGFR TKIs, 2016-2026
  • Figure 15: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Other TKIs, 2016-2026
  • Figure 16: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 17: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 18: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by CML, 2016-2026
  • Figure 19: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lung Cancer, 2016-2026
  • Figure 20: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Renal Cell Cancer, 2016-2026
  • Figure 21: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2016-2026
  • Figure 22: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016-2026
  • Figure 23: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 24: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 25: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016-2026
  • Figure 26: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2016-2026
  • Figure 27: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016-2026
  • Figure 28: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 29: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Region/Country, 2017 and 2026
  • Figure 30: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Region/Country, 2018-2026
  • Figure 31: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 32: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 33: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 34: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 35: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 36: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 37: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 38: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 39: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 40: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 41: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 42: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 43: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 44: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 45: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 46: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 47: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 48: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 49: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 50: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 51: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 52: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 53: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 54: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 55: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 56: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 57: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 58: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 59: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 60: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 61: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 62: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018 -2026
  • Figure 63: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 64: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 65: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 66: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 67: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 68: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 69: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 70: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 71: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018 -2026
  • Figure 72: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 73: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 - 2026
  • Figure 74: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 75: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 76: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 77: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 78: Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 79: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 80: Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 81: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 82: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018-2026
  • Figure 83: Global Tyrosine Kinase Inhibitors Market Share, by Company, 2017
目次

Title:
Tyrosine Kinase Inhibitors Market (Product - BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors, Other Tyrosine Kinase Inhibitors; Application - Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer; Distribution Channel - Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Tyrosine Kinase Inhibitors Market - Overview

This report on the tyrosine kinase inhibitors market analyzes the current and future scenario of the global market. Increasing expenditure on health care, high prevalence and rise in incidence of cancer, and rise in demand for tyrosine kinase inhibitors for lungs cancer & breast cancer treatment are boosting the usage of tyrosine kinase inhibitors. Health benefits of tyrosine kinase inhibitors and focus of companies on expanding indications of existing and pipeline TKIs are major drivers of the global tyrosine kinase inhibitors market.

The tyrosine kinase inhibitors market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, application, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises product portfolios of major players, based on constituents & application, in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography, and market share analysis by key players. Thus, presenting a thorough analysis of the overall competitive scenario in the global tyrosine kinase inhibitors market.

Based on product, the market has been segmented into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors, and other tyrosine kinase inhibitors. The product segment of tyrosine kinase inhibitors market has been analyzed based on available approved products, cost-effectiveness, and preference provided by physicians and patients in treating different cancer diseases. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year.

Based on application, the market has been classified into chronic myeloid leukemia (CML), lung cancer, breast cancer, renal cell cancer, and others. The application segment of tyrosine kinase inhibitors market has been analyzed based on the prevalence of disease and usage of tyrosine kinase inhibitors in treatment. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year.

In terms of distribution channel, the tyrosine kinase inhibitors market has been segregated into hospital pharmacies, independent pharmacies, and online pharmacies. The market segments have been extensively analyzed based on prevalence of the diseases and usage of tyrosine kinase inhibitors during available treatment and expansion of international pharmacy service providers across the globe. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each market segment for the period from 2018 to 2026, considering 2017 as the base year.

In terms of geography, the global tyrosine kinase inhibitors market has been categorized into six major regions and the key countries in the respective region are: North America (U.S., Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (Japan, India, China, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East (UAE, Saudi Arabia, and Rest of Middle East) and Africa (South Africa and Rest of Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global tyrosine kinase inhibitors market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca Plc, Pfizer, Inc., Novartis AG, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Eisai Co., Ltd., and Eurofarma Laboratorios S/A.

Global tyrosine kinase inhibitors market has been segmented as given below:

Global Tyrosine Kinase Inhibitors Market, by Product, 2016-2026

  • BCR-ABL Tyrosine Kinase Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
  • Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
  • Other Tyrosine Kinase Inhibitors (Janus Kinase Inhibitors, Bruton's Kinase Inhibitor, HGFR TKIs, ALK / ROS1 TKIs, etc.)

Global Tyrosine Kinase Inhibitors Market, by Application, 2016-2026

  • Chronic Myeloid Leukemia (CML)
  • Lung Cancer
  • Breast Cancer
  • Renal Cell Cancer
  • Others

Global Tyrosine Kinase Inhibitors Market, by Distribution Channel, 2016-2026

  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies

Global Tyrosine Kinase Inhibitors Market, by Geography, 2016-2026

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East
    • Saudi Arabia
    • UAE
    • Rest of Middle East
  • Africa
    • South Africa
    • Rest of Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Tyrosine Kinase Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunity
    • 4.3.4. Key Trends
  • 4.4. Global Tyrosine Kinase Inhibitors Market Analysis and Forecasts, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Global Tyrosine Kinase Inhibitors Market Outlook

  • 5.1. Key Brand / Product Analysis
  • 5.2. Patent & Market Exclusivity Analysis
  • 5.3. Overview of Approved Indications
  • 5.4. Tyrosine Kinase Inhibitors - Clinical Trial Analysis
  • 5.5. Recent Industry Developments
  • 5.6. Pipeline Analysis
  • 5.7. Key Mergers & Acquisitions

6. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 6.3.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 6.3.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 6.3.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 6.3.4. Other Tyrosine Kinase Inhibitors
  • 6.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Product

7. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 7.3.1. Chronic Myeloid Leukemia (CML)
    • 7.3.2. Lung Cancer
    • 7.3.3. Breast Cancer
    • 7.3.4. Renal Cell Cancer
    • 7.3.5. Others
  • 7.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Application

8. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Independent Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Distribution Channel

9. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Tyrosine Kinase Inhibitors Market Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East &Africa
  • 9.3. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Country/Region

10. North America Tyrosine Kinase Inhibitors Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 10.2.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 10.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 10.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 10.2.4. Other Tyrosine Kinase Inhibitors
  • 10.3. North America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 10.3.1. Chronic Myeloid Leukemia (CML)
    • 10.3.2. Lung Cancer
    • 10.3.3. Breast Cancer
    • 10.3.4. Renal Cell Cancer
    • 10.3.5. Others
  • 10.4. North America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Independent Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. North America Tyrosine Kinase Inhibitors Market Forecast, by Country, 2016-2026
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis
    • 10.6.1. By Product
    • 10.6.2. By Application
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Tyrosine Kinase Inhibitors Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 11.2.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 11.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 11.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 11.2.4. Other Tyrosine Kinase Inhibitors
  • 11.3. Europe Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 11.3.1. Chronic Myeloid Leukemia (CML)
    • 11.3.2. Lung Cancer
    • 11.3.3. Breast Cancer
    • 11.3.4. Renal Cell Cancer
    • 11.3.5. Others
  • 11.4. Europe Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Independent Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Europe Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016-2026
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis
    • 11.6.1. By Product
    • 11.6.2. By Application
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country

12. Asia Pacific Tyrosine Kinase Inhibitors Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 12.2.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 12.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 12.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 12.2.4. Other Tyrosine Kinase Inhibitors
  • 12.3. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 12.3.1. Chronic Myeloid Leukemia (CML)
    • 12.3.2. Lung Cancer
    • 12.3.3. Breast Cancer
    • 12.3.4. Renal Cell Cancer
    • 12.3.5. Others
  • 12.4. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Independent Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5.Market Forecast, by Country, 2016-2026
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis
    • 12.6.1. By Product
    • 12.6.2. By Application
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country

13. Latin America Tyrosine Kinase Inhibitors Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 13.2.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 13.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 13.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 13.2.4. Other Tyrosine Kinase Inhibitors
  • 13.3. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 13.3.1. Chronic Myeloid Leukemia (CML)
    • 13.3.2. Lung Cancer
    • 13.3.3. Breast Cancer
    • 13.3.4. Renal Cell Cancer
    • 13.3.5. Others
  • 13.4. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Independent Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016-2026
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis
    • 13.6.1. By Product
    • 13.6.2. By Application
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Middle East Tyrosine Kinase Inhibitors Market Analysis and Forecast

  • 14.1.Introduction
    • 14.1.1. Key Findings
  • 14.2. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 14.2.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 14.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 14.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 14.2.4. Other Tyrosine Kinase Inhibitors
  • 14.3. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 14.3.1. Chronic Myeloid Leukemia (CML)
    • 14.3.2. Lung Cancer
    • 14.3.3. Breast Cancer
    • 14.3.4. Renal Cell Cancer
    • 14.3.5. Others
  • 14.4. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Independent Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016-2026
    • 14.5.1. UAE
    • 14.5.2. Saudi Arabia
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis
    • 14.6.1. By Product
    • 14.6.2. By Application
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country

15. Africa Tyrosine Kinase Inhibitors Market Analysis and Forecast

  • 15.1.Introduction
    • 15.1.1. Key Findings
  • 15.2. Africa Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016-2026
    • 15.2.1. BCR-ABL Tyrosine Kinase Inhibitors
    • 15.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 15.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 15.2.4. Other Tyrosine Kinase Inhibitors
  • 15.3. Africa Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016-2026
    • 15.3.1. Chronic Myeloid Leukemia (CML)
    • 15.3.2. Lung Cancer
    • 15.3.3. Breast Cancer
    • 15.3.4. Renal Cell Cancer
    • 15.3.5. Others
  • 15.4. Africa Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016-2026
    • 15.4.1. Hospital Pharmacies
    • 15.4.2. Independent Pharmacies
    • 15.4.3. Online Pharmacies
  • 15.5. Africa Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016-2026
    • 15.5.1. South Africa
    • 15.5.2. Rest of Africa
  • 15.6. Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis
    • 15.6.1. By Product
    • 15.6.2. By Application
    • 15.6.3. By Distribution Channel

16. Competition Landscape

  • 16.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2.Global Tyrosine Kinase Inhibitors Market Snapshot of Companies (2017)
  • 16.3.Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 16.3.1. AstraZeneca Plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Strategic Overview
    • 16.3.2. Pfizer, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Strategic Overview
    • 16.3.3. Novartis AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Strategic Overview
    • 16.3.4. Bristol-Myers Squibb Company
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Strategic Overview
    • 16.3.5. Bayer AG
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Strategic Overview
    • 16.3.6. Boehringer Ingelheim International GmbH
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Strategic Overview
      • 16.3.6.5. Financial
    • 16.3.7. F. Hoffmann-La Roche Ltd.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Strategic Overview
    • 16.3.8. Johnson & Johnson
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. SWOT Analysis
      • 16.3.8.4. Strategic Overview
    • 16.3.9. Eisai Co., Ltd.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. SWOT Analysis
      • 16.3.9.4. Strategic Overview
    • 16.3.10. Eurofarma Laboratorios S/A
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. SWOT Analysis
      • 16.3.10.4. Strategic Overview
Back to Top